lorazepam has been researched along with Alcohol Drinking in 15 studies
Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.
Alcohol Drinking: Behaviors associated with the ingesting of ALCOHOLIC BEVERAGES, including social drinking.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The authors present three patients with alcoholism in whom diagnosis of panic was facilitated by intravenous lactate infusion, and whose symptoms were alleviated by clonazepam." | 3.68 | The diagnosis and treatment of panic disorder in alcoholics: three cases. ( Baron, DH; Ciraulo, DA; Sands, BF; Shader, RI, 1990) |
| "Lorazepam was used as rescue medication." | 2.82 | A randomized, open-label, standard controlled, parallel group study of efficacy and safety of baclofen, and chlordiazepoxide in uncomplicated alcohol withdrawal syndrome. ( Girish, K; Manjunatha, R; Nagraj, M; Pandit, LV; Pundarikaksha, HP; Shruthi, R; Vasundara, K; Vijendra, R; Vikram Reddy, K, 2016) |
| "Post-treatment, gabapentin-treated participants had less probability of drinking during the follow-up post-treatment period (p = 0." | 2.74 | A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal. ( Anton, RF; Becker, HC; Boyle, E; Malcolm, R; Myrick, H; Randall, CL; Randall, PK, 2009) |
| "Lorazepam was an effective night sedative." | 1.26 | Premedication with lorazepam for bronchoscopy under general anaesthesia. ( Barr, AM; Hewitt, JM, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 5 (33.33) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Daurat, A | 1 |
| Sagaspe, P | 1 |
| Moták, L | 1 |
| Taillard, J | 1 |
| Bayssac, L | 1 |
| Huet, N | 1 |
| Authié, C | 1 |
| Mestre, D | 1 |
| Philip, P | 1 |
| Huang, MC | 1 |
| Chen, CH | 1 |
| Pan, CH | 1 |
| Lin, SK | 1 |
| Rose, L | 1 |
| Burry, L | 1 |
| Mallick, R | 1 |
| Luk, E | 1 |
| Cook, D | 1 |
| Fergusson, D | 1 |
| Dodek, P | 1 |
| Burns, K | 1 |
| Granton, J | 1 |
| Ferguson, N | 1 |
| Devlin, JW | 1 |
| Steinberg, M | 1 |
| Keenan, S | 1 |
| Reynolds, S | 1 |
| Tanios, M | 1 |
| Fowler, RA | 1 |
| Jacka, M | 1 |
| Olafson, K | 1 |
| Skrobik, Y | 1 |
| Mehta, S | 1 |
| Girish, K | 1 |
| Vikram Reddy, K | 1 |
| Pandit, LV | 1 |
| Pundarikaksha, HP | 1 |
| Vijendra, R | 1 |
| Vasundara, K | 1 |
| Manjunatha, R | 1 |
| Nagraj, M | 1 |
| Shruthi, R | 1 |
| Myrick, H | 1 |
| Malcolm, R | 1 |
| Randall, PK | 1 |
| Boyle, E | 1 |
| Anton, RF | 1 |
| Becker, HC | 1 |
| Randall, CL | 1 |
| Hulin, MW | 1 |
| Amato, RJ | 1 |
| Winsauer, PJ | 1 |
| Jackson, A | 2 |
| Stephens, DN | 1 |
| Duka, T | 2 |
| Maccioli, GA | 1 |
| Stephens, D | 1 |
| Cohen, SI | 1 |
| Nichols, JM | 2 |
| Martin, F | 2 |
| Kirkby, KC | 1 |
| Naassila, M | 1 |
| Legrand, E | 1 |
| d'Alche-Birée, F | 1 |
| Daoust, M | 1 |
| Hewitt, JM | 1 |
| Barr, AM | 1 |
| Baron, DH | 1 |
| Sands, BF | 1 |
| Ciraulo, DA | 1 |
| Shader, RI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Trial of Daily Sedative Interruption in Critically Ill, Mechanically Ventilated Patients Being Managed With a Sedation Protocol[NCT00675363] | 410 participants (Anticipated) | Interventional | 2008-01-31 | Completed | |||
| Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776] | Phase 2 | 54 participants (Actual) | Interventional | 2017-08-07 | Completed | ||
| A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Dexmedetomidine (Precedex®), With Lorazepam Rescue, for the Management of Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)[NCT01362205] | Phase 4 | 49 participants (Actual) | Interventional | 2012-03-31 | Terminated (stopped due to DSMB recommendation for slow enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 3.90 |
| Gabapentin | 3.93 |
| Placebo Oral Tablet | 3.73 |
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 21.59 |
| Gabapentin | 21.69 |
| Placebo Oral Tablet | 22.25 |
Minnesota Detoxification Scale (MINDS) min score 0, max score 46. The higher the score, the worse the symptoms of AWS/AWD. (NCT01362205)
Timeframe: up to 28 days
| Intervention | units on a scale (Median) |
|---|---|
| Dexmedetomidine | 8.2 |
| Placebo | 9.4 |
A ventilator day is counted for any use of invasive mechanical ventilation during a calendar day (NCT01362205)
Timeframe: up to 28 days
| Intervention | days (Median) |
|---|---|
| Dexmedetomidine | 27.5 |
| Placebo | 28.0 |
(NCT01362205)
Timeframe: Up to 28 days
| Intervention | USD (Median) |
|---|---|
| Dexmedetomidine | 81234 |
| Placebo | 91651 |
(NCT01362205)
Timeframe: up to 28 Days
| Intervention | Dollar (United States) (Median) |
|---|---|
| Dexmedetomidine | 3482 |
| Placebo | 4461 |
The Beck Anxiety Inventory is a validated questionnaire used to measure severity of anxiety (min score 0, max score 63). The higher the score the greater the severity of anxiety. A score of 30-63 indicates severe anxiety, 17-29 moderate anxiety, 10-16 mild anxiety and 0-9 minimal anxiety. (NCT01362205)
Timeframe: Up to 28 days.
| Intervention | units on a scale (Mean) |
|---|---|
| Dexmedetomidine | 30.3 |
| Placebo | 21.6 |
The Beck Depression Inventory is a validated questionnaire used to measure severity of depression (min score 0, max score 63). The higher the score the greater the severity of depression. A score of 30-63 indicates severe depression, 19-29 moderate depression, 10-18 mild depression and 0-9 minimal depression. (NCT01362205)
Timeframe: Up to 28 days.
| Intervention | units on a scale (Mean) |
|---|---|
| Dexmedetomidine | 26.5 |
| Placebo | 21.4 |
The Mini Mental State Examination or Folstein test is a validated 30-point questionnaire used to measure cognitive impairment (min score 0, max score 30). A score of 24 points (out of a max of 30) indicates normal cognition, less than or equal to 9 points indicates severe impairment, 10-18 indicates moderate impairment and 19-23 mild impairment. (NCT01362205)
Timeframe: up to 28 days
| Intervention | units on a scale (Mean) |
|---|---|
| Dexmedetomidine | 25.8 |
| Placebo | 23.1 |
PTSD checklist consists of 17 questions graded on a scale of 1 to 5. The PTSD score is comprised from the sum of the scores 17 questions. The PTSD score has possible values from to 17 to 85 with higher values indicating greater symptom severity. (NCT01362205)
Timeframe: Up to 28 days
| Intervention | units on a scale (Median) |
|---|---|
| Dexmedetomidine | 45.5 |
| Placebo | 32.5 |
A hospital day is counted for any time on a calendar day the patient is admitted to the hospital. Hospital days are inclusive of ICU days. (NCT01362205)
Timeframe: up to 28 days
| Intervention | days (Median) |
|---|---|
| Dexmedetomidine | 8.0 |
| Placebo | 12.0 |
(NCT01362205)
Timeframe: up to 28 days in hours
| Intervention | hours (Median) |
|---|---|
| Dexmedetomidine | 79.2 |
| Placebo | 104.9 |
The Confusion Assessment Method (CAM)-ICU is a validated instrument used to detect the presence or absence of delirium in the ICU. A delirium free day is counted for any day a patient is negative by the CAM-ICU. The higher the number of CAM-ICU negative days indicates the more days a patient was able to think clearly. (NCT01362205)
Timeframe: up to 28 days
| Intervention | days (Median) |
|---|---|
| Dexmedetomidine | 0.3 |
| Placebo | 0.3 |
8 trials available for lorazepam and Alcohol Drinking
| Article | Year |
|---|---|
Lorazepam impairs highway driving performance more than heavy alcohol consumption.
Topics: Adult; Alcohol Drinking; Anti-Anxiety Agents; Automobile Driving; Computer Simulation; Cross-Over St | 2013 |
Lack of efficacy of dextromethorphan in managing alcohol withdrawal: a preliminary report of a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Alcohol Abstinence; Alcohol Drinking; Alcoholism; Brain; Dextromethorphan; Double-Blind Metho | 2014 |
Prevalence, risk factors, and outcomes associated with physical restraint use in mechanically ventilated adults.
Topics: Adult; Aged; Alcohol Drinking; Analgesics, Opioid; Antipsychotic Agents; Benzodiazepines; Clinical P | 2016 |
A randomized, open-label, standard controlled, parallel group study of efficacy and safety of baclofen, and chlordiazepoxide in uncomplicated alcohol withdrawal syndrome.
Topics: Adult; Alcohol Drinking; Baclofen; Chlordiazepoxide; Diazepam; Humans; Lorazepam; Male; Middle Aged; | 2016 |
A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal.
Topics: Adult; Alcohol Drinking; Amines; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Doub | 2009 |
Gender differences in response to lorazepam in a human drug discrimination study.
Topics: Adolescent; Adult; Alcohol Drinking; Anti-Anxiety Agents; Attention; Discrimination Learning; Double | 2005 |
A comparison of the effect of lorazepam on memory in heavy and low social drinkers.
Topics: Adult; Alcohol Drinking; Double-Blind Method; Humans; Lorazepam; Male; Maze Learning; Memory; Mental | 1993 |
The effect of lorazepam on memory and event-related potentials in heavy and light social drinkers.
Topics: Adult; Alcohol Drinking; Anti-Anxiety Agents; Double-Blind Method; Electroencephalography; Evoked Po | 1996 |
7 other studies available for lorazepam and Alcohol Drinking
| Article | Year |
|---|---|
GABA(A) receptor modulation during adolescence alters adult ethanol intake and preference in rats.
Topics: Aging; Alcohol Drinking; Animals; Data Interpretation, Statistical; Dehydroepiandrosterone; Dose-Res | 2012 |
Lorazepam substitutes for the alcohol stimulus in social drinkers.
Topics: Adolescent; Adult; Alcohol Drinking; Anti-Anxiety Agents; Confusion; Discrimination Learning; Ethano | 2003 |
Dexmedetomidine to facilitate drug withdrawal.
Topics: Alcohol Drinking; Blood Pressure; Cocaine-Related Disorders; Dexmedetomidine; Female; Heart Rate; Hu | 2003 |
Alcohol and benzodiazepines generate anxiety, panic and phobias.
Topics: Adult; Aged; Alcohol Drinking; Alcoholism; Anti-Anxiety Agents; Anxiety Disorders; Diazepam; Female; | 1995 |
Cyamemazine decreases ethanol intake in rats and convulsions during ethanol withdrawal syndrome in mice.
Topics: Alcohol Deterrents; Alcohol Drinking; Animals; Anti-Anxiety Agents; Antipsychotic Agents; Central Ne | 1998 |
Premedication with lorazepam for bronchoscopy under general anaesthesia.
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Anesthesia, General; Anti-Anxiety Agents; Bronchoscopy; F | 1978 |
The diagnosis and treatment of panic disorder in alcoholics: three cases.
Topics: Adult; Alcohol Drinking; Alcoholism; Anxiety Disorders; Clonazepam; Diazepam; Follow-Up Studies; Hum | 1990 |